LAQUINIMOD IMMUNOMODULATORY ACTION CONFERS BOTH

Results Presented at 25th Congress of the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS)

Jerusalem, Israel  and  Lund,  Sweden,  September  11,  2009  -  Teva
Pharmaceutical Industries  Ltd.  (NASDAQ: TEVA)  and  Active  Biotech
(NASDAQ OMX NORDIC: ACTI)  today presented data further  illuminating
the novel, dual  mechanism of action  (MOA) of investigational  oral,
once-daily,  laquinimod  for  the  treatment  of  relapsing-remitting
multiple   sclerosis   (RRMS),    conferring   neuroprotective    and
anti-inflammatory  properties.  Results   from  several   preclinical
studies suggest  that  laquinimod elicits  a  protective  therapeutic
effect by reducing demyelination and inducing axonal protection.

Read the complete press release below.


Contact: Elana Holzman    Teva Pharmaceutical       +972-(3)-926-7554
         Kevin Mannix     Industries Ltd.           +1-(215)-591-8912
                          Teva North America
         Tomas Leanderson Active Biotech AB         +46-46-19-20-95
         Göran Forsberg   Active Biotech AB         +46-46-19-11-54

LAQUINIMOD IMMUNOMODULATORY ACTION CONFERS BOTH NEUROPROTECTIVE AND ANTI-INFLAMMATORY PROPERTIES

Attachments